This product is a recombinant rabbit antibody that recognizes HVEM. The antibody was purified by affinity chromatography. It can be used in Block, FuncS, IP, WB, FC.
Figure 1 Anti-BTLA or anti-HVEM antibody treatment during the effector phase does not affect conjunctival eosniophilia in EC.
EC was induced in BALB/c mice by immunization with RW in alum following RW challenge. The mice were intraperitoneally injected with anti-BTLA antibody, anti-HVEM antibody or control nhIgG once before RW challenge. Data are presented as eosinophil counts per conjunctiva.
Ishida, W., Fukuda, K., Kajisako, M., Sumi, T., Matsuda, H., Yagita, H., & Fukushima, A. (2012). B and T lymphocyte attenuator regulates the development of antigen-induced experimental conjunctivitis. Graefe's Archive for Clinical and Experimental Ophthalmology, 250(2), 289-295.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
VS-0723-WK264 | Rabbit Anti-HVEM Recombinant Antibody (VS-0723-WK264) | ELISA, FC | Rabbit IgG |
There are currently no Customer reviews or questions for FAMAB-1384CQ. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.